Caption Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-63,500
| Closed | -$2.55M | – | 1633 |
|
|
2026
Q1 | $2.55M | Sell |
63,500
-539,200
| -89% | -$11.6M | 0.01% | 753 |
|
|
2025
Q4 | $15.1M | Buy |
602,700
+2,300
| +0.4% | +$54K | 0.1% | 236 |
|
|
2025
Q3 | $13.6M | Buy |
600,400
+85,400
| +17% | +$1.99M | 0.11% | 203 |
|
|
2025
Q2 | $8.91M | Buy |
515,000
+375,000
| +268% | +$6.94M | 0.1% | 235 |
|
|
2025
Q1 | $3.06M | Sell |
140,000
-526,800
| -79% | -$14.6M | 0.03% | 545 |
|
|
2024
Q4 | $21.3M | Buy |
666,800
+76,800
| +13% | +$2.31M | 0.2% | 76 |
|
|
2024
Q3 | $17M | Sell |
590,000
-414,700
| -41% | -$15.4M | 0.27% | 85 |
|
|
2024
Q2 | $38.5M | Buy |
1,004,700
+944,700
| +1,575% | +$42.8M | 0.59% | 37 |
|
|
2024
Q1 | $3.53M | Sell |
60,000
-276,400
| -82% | -$17.6M | 0.05% | 381 |
|
|
2023
Q4 | $20.1M | Sell |
336,400
-250,800
| -43% | -$12.7M | 0.27% | 78 |
|
|
2023
Q3 | $22.3M | Buy |
587,200
+421,700
| +255% | +$18.5M | 0.34% | 60 |
|
|
2023
Q2 | $15.1M | Sell |
165,500
-385,000
| -70% | -$33.2M | 0.27% | 86 |
|
|
2023
Q1 | $36.3M | Buy |
550,500
+515,500
| +1,473% | +$29.7M | 0.7% | 24 |
|
|
2022
Q4 | $1.81M | Sell |
35,000
-30,000
| -46% | -$1.59M | 0.03% | 582 |
|
|
2022
Q3 | $4.44M | Buy |
+65,000
| New | +$3.85M | 0.06% | 384 |
|
|
2022
Q2 | – | Sell |
-65,300
| Closed | -$3.32M | – | 1419 |
|
|
2022
Q1 | $3.32M | Buy |
65,300
+35,300
| +118% | +$1.56M | 0.04% | 576 |
|
|
2021
Q4 | $1.42M | Sell |
30,000
-490,900
| -94% | -$19.3M | 0.02% | 917 |
|
|
2021
Q3 | $17.2M | Buy |
520,900
+335,900
| +182% | +$18.9M | 0.2% | 122 |
|
|
2021
Q2 | $11.7M | Buy |
185,000
+138,000
| +294% | +$7.12M | 0.15% | 164 |
|
|
2021
Q1 | $2.02M | Buy |
+47,000
| New | +$2.22M | 0.04% | 511 |
|
|
2020
Q4 | – | Sell |
-30,000
| Closed | -$904K | – | 954 |
|
|
2020
Q3 | $904K | Buy |
+30,000
| New | +$896K | 0.02% | 640 |
|
|
2020
Q2 | – | Sell |
-5,400
| Closed | -$144K | – | 919 |
|
|
2020
Q1 | $144K | Sell |
5,400
-100,000
| -95% | -$3.55M | 0.01% | 737 |
|
|
2019
Q4 | $3.23M | Buy |
+105,400
| New | +$2.92M | 0.11% | 259 |
|
Other funds holding APLS
Caption Management's APLS Position: Q1 2026 in Review
Caption Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 254,563 shares — an estimated $5.49M sold.
Caption Management first reported a position in APLS in Q1 2021 and held it in 15 quarters. The position peaked at $23.5M in Q4 2023. 324 funds tracked by Wall St. Rank hold APLS as of Q1 2026.
- Caption Management reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Caption Management sold 254,563 Apellis Pharmaceuticals shares in Q1 2026, an estimated $5.49M.
- Caption Management first reported a position in Apellis Pharmaceuticals in Q1 2021 and held it in 15 quarters.
- Caption Management's Apellis Pharmaceuticals position peaked at $23.5M in Q4 2023.
- 324 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.
Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.